Cargando…

A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells

The signaling lymphocyte activation molecule family [SLAMF] of cell surface receptors partakes in both the development of several immunocyte lineages and innate and adaptive immune responses in humans and mice. For instance, the homophilic molecule SLAMF6 (CD352) is in part involved in natural kille...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yigit, Burcu, Halibozek, Peter J., Chen, Shih-Shih, O'Keeffe, Michael S., Arnason, Jon, Avigan, David, Gattei, Valter, Bhan, Atul, Cen, Osman, Longnecker, Richard, Chiorazzi, Nicholas, Wang, Ninghai, Engel, Pablo, Terhorst, Cox
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041984/ https://www.ncbi.nlm.nih.gov/pubmed/27029059 http://dx.doi.org/10.18632/oncotarget.8378

Ejemplares similares

Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors
por: Wang, Ninghai, et al.
Publicado: (2015)

Migration of Myeloid Cells during Inflammation Is Differentially Regulated by the Cell Surface Receptors Slamf1 and Slamf8
por: Wang, Guoxing, et al.
Publicado: (2015)

SAP-Dependent and -Independent Regulation of Innate T Cell Development Involving SLAMF Receptors
por: De Calisto, Jaime, et al.
Publicado: (2014)

The Checkpoint Regulator SLAMF3 Preferentially Prevents Expansion of Auto-Reactive B Cells Generated by Graft-vs.-Host Disease
por: Wang, Ninghai, et al.
Publicado: (2019)

Responses to Microbial Challenges by SLAMF Receptors
por: van Driel, Boaz Job, et al.
Publicado: (2016)

SLAMF1 is required for TLR4-mediated TRAM-TRIF–dependent signaling in human macrophages
por: Yurchenko, Maria, et al.
Publicado: (2018)

CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development
por: Huang, Bonnie, et al.
Publicado: (2016)

The Receptor Slamf1 on the Surface of Myeloid Lineage Cells Controls Susceptibility to Infection by Trypanosoma cruzi
por: Calderón, Jossela, et al.
Publicado: (2012)

SLAMF8 Downregulates Mouse Macrophage Microbicidal Mechanisms via PI3K Pathways
por: Romero-Pinedo, Salvador, et al.
Publicado: (2022)

CRISPR-Mediated Slamf1(Δ/Δ) Slamf5(Δ/Δ) Slamf6(Δ/Δ) Triple Gene Disruption Reveals NKT Cell Defects but Not T Follicular Helper Cell Defects
por: Hu, Joyce K., et al.
Publicado: (2016)

SLAMF6 compartmentalization enhances T cell functions
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2022)

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia
por: Frezzato, Federica, et al.
Publicado: (2021)

SLAMF6 clustering is required to augment T cell activation
por: Dragovich, Matthew A., et al.
Publicado: (2019)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Clinical impact of serum soluble SLAMF7 in multiple myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2018)

The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis
por: Gonçalves-Carneiro, Daniel, et al.
Publicado: (2017)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

SLAMF6 is associated with the susceptibility and severity of rheumatoid arthritis in the Chinese population
por: Xia, Guodong, et al.
Publicado: (2022)

SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis
por: Wu, Yongjian, et al.
Publicado: (2023)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
por: Chu, Emily, et al.
Publicado: (2023)

Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
por: He, Yuan, et al.
Publicado: (2019)

SLAMF1 Promotes Methotrexate Resistance via Activating Autophagy in Choriocarcinoma Cells
por: Shi, Dazun, et al.
Publicado: (2020)

SLAMF Receptor Expression Identifies an Immune Signature That Characterizes Systemic Lupus Erythematosus
por: Humbel, Morgane, et al.
Publicado: (2022)

SLAMF1 contributes to cell survival through the AKT signaling pathway in Farage cells
por: Yoon, Heejei, et al.
Publicado: (2020)

Evidence for the loss and recovery of SLAMF9 during human evolution: implications on Dollo’s law
por: Murphy, Maegan K., et al.
Publicado: (2021)

Advances in Understanding the Roles of CD244 (SLAMF4) in Immune Regulation and Associated Diseases
por: Sun, Lin, et al.
Publicado: (2021)

SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers
por: Zhang, Qun, et al.
Publicado: (2021)

SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity
por: O’Connell, Patrick, et al.
Publicado: (2022)

Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukemia
por: Del Poeta, Giovanni, et al.
Publicado: (2020)

The Expression of the Hepatocyte SLAMF3 (CD229) Receptor Enhances the Hepatitis C Virus Infection
por: Cartier, Flora, et al.
Publicado: (2014)

Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression
por: Marcq, Ingrid, et al.
Publicado: (2013)

The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5
por: Radomir, Lihi, et al.
Publicado: (2021)

SLAMF8, a potential new immune checkpoint molecule, is associated with the prognosis of colorectal cancer
por: Zhang, Yaping, et al.
Publicado: (2023)

Peptide derived from SLAMF1 prevents TLR4-mediated inflammation in vitro and in vivo
por: Nilsen, Kaja Elisabeth, et al.
Publicado: (2023)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Butylidenephthalide Abrogates the Snail-Induced Cancer Stemness in Oral Carcinomas
por: Chen, Pei-Yin, et al.
Publicado: (2022)

P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
por: Pozzo, Federico, et al.
Publicado: (2023)

The Minor Variant of the Single-Nucleotide Polymorphism rs3753381 Affects the Activity of a SLAMF1 Enhancer
por: Putlyaeva, L.V., et al.
Publicado: (2017)

Integrated DNA methylation and gene expression analysis identifies SLAMF7 as a key regulator of atherosclerosis
por: Xia, Zhangyong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l6rdcijm58s5hgm939pv1ji6k0